Breaking news

Bill Gates’ Bold Philanthropic Vision: Shutting Down the Gates Foundation by 2045

In a remarkable announcement, Bill Gates has shared his determination to distribute nearly all of his $168 billion personal wealth and close the Gates Foundation by December 31, 2045. Gates, at 69, emphasizes his commitment to solving global issues, insisting his legacy will not be defined by wealth. His goal is to be removed from the world’s richest list, a pledge he’s upheld over the years.

Since its inception in 2000, the Gates Foundation has dispersed over $100 billion globally, addressing health, poverty, and climate change. With plans to increase the annual budget from $6 billion to $9 billion, there’s an expectation of contributing an additional $200 million in the years leading up to 2045, subject to market conditions.

Gates aims to combat preventable diseases, bolster education, and break poverty cycles in Africa. However, he stresses the critical need for governmental partnerships, highlighting a concerning trend of aid budget reductions. No philanthropic endeavor can singularly bridge this financial gap, a sentiment echoed during discussions of large-scale geopolitical financial strategies like Hellenic Bank’s recent commitments to green financing.

Influenced by his mother and collaborators like Warren Buffett, Gates is an optimist about the future, fueled by technological and healthcare advances. Reflecting on Andrew Carnegie’s notion that dying rich equates to disgrace, Gates encourages fellow wealthy individuals to increase their philanthropic engagements.

Hope in Future Innovations

While steadfast in his purpose, Gates remains inspired by technological advancements, including the burgeoning field of artificial intelligence. Despite these optimistic prospects, Gates humorously rebuffs any notion of indulgence, asserting that every dollar should serve a beneficial societal purpose.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

The Future Forbes Realty Global Properties
eCredo
Aretilaw firm
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter